Clinical Trials Logo

Filter by:
  • No longer available  
  • Page [1]
NCT ID: NCT02783001 No longer available - HIV Infections Clinical Trials

Expanded Access Program for Maraviroc At Multiple Centers

Start date: n/a
Phase: Phase 3
Study type: Expanded Access

To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

NCT ID: NCT01947608 No longer available - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Start date: n/a
Phase:
Study type: Expanded Access

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.

NCT ID: NCT01582438 No longer available - Clinical trials for Pulmonary Arterial Hypertension

An Open Label Access Study For Subjects Who Completed A1481156

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil citrate. Sildenafil citrate will be supplied for the treatment of Pulmonary Arterial Hypertension (PAH) until the subject continues to derive benefits from the treatment. The treating physicians (and the sponsor) will be responsible for reporting serious adverse events.

NCT ID: NCT00878943 No longer available - Clinical trials for Pulmonary Arterial Hypertension

Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study

UK 92480
Start date: n/a
Phase:
Study type: Expanded Access

In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo. This protocol provides mechanism for patients who have clinical deterioration on other PAH approved therapies to have access to sildenafil prior to marketing authorization in India.